Search Results for keywords:"Drug Enforcement Administration"

The Drug Enforcement Administration (DEA) has decided to revoke Jason Lee Ray's DEA Certificate of Registration because he cannot legally handle controlled substances in Wyoming. This decision follows the suspension of his Wyoming physician assistant license by the Wyoming Board of Medicine. The DEA's decision emphasizes the necessity of being authorized at the state level to dispense controlled substances to maintain a DEA registration. Any applications by Jason Lee Ray to renew or modify his registration are also denied, effective January 29, 2025.

The Drug Enforcement Administration proposes to make seven fentanyl-related substances permanently controlled under Schedule I of the Controlled Substances Act. These substances, identified as dangerous opioids, are currently regulated under a temporary order due to their potential for abuse and health hazards. If this proposal is finalized, it would enforce permanent restrictions and legal penalties on the handling of these substances, which include para-chlorofentanyl and ortho-chlorofentanyl. The public is encouraged to submit comments on this rule by January 29, 2025.

Organic Consultants LLC, doing business as Cascade Chemistry, has applied to the Drug Enforcement Administration (DEA) to become a bulk manufacturer of certain controlled substances. Interested parties have until April 1, 2025, to submit comments or objections regarding the application or to request a hearing. Comments can be submitted electronically through the Federal eRulemaking Portal. The company intends to produce small amounts of these substances for internal use or to sell as analytical reference standard materials, with no other activities authorized for these drug codes.

The Drug Enforcement Administration (DEA) is notifying the public of an application from JW Colorado, LLC, to be registered as a bulk manufacturer of marihuana, a controlled substance listed under schedule I. The DEA will evaluate the application along with others under regulations meant to ensure that the growth of marihuana is for legitimate scientific and medical research purposes. Written comments or objections to this proposed registration must be submitted by April 19, 2021, and the evaluation will ensure compliance with all relevant laws and safeguards against misuse.

The Drug Enforcement Administration (DEA) has received an application from Titan Health LLC to become registered to manufacture bulk quantities of marihuana for research purposes. This notice invites current registered bulk manufacturers and applicants to submit comments or objections by April 19, 2021. The DEA will review the application according to regulations to ensure compliance with legal requirements and prevent unlawful distribution. If approved, Titan Health LLC would be authorized to manufacture pharmaceuticals for research but not engage in other activities without additional approval.

The Drug Enforcement Administration (DEA) has announced that the University of Kentucky Cannabis Center has applied to become a registered bulk manufacturer of controlled substances, specifically marihuana. This application, filed on July 1, 2024, aims to allow the center to produce bulk active pharmaceutical ingredients for research purposes. Interested parties can comment on or object to this application until April 14, 2025, through the Federal eRulemaking Portal. DEA will review the application to ensure it complies with laws and regulations, focusing on preventing the potential diversion of the controlled substance.

Veranova, L.P. has applied to become a registered bulk manufacturer of specific controlled substances. The application has been submitted to the Drug Enforcement Administration (DEA) to support their manufacturing and analytical testing needs. Public comments or objections regarding this application can be submitted electronically through the Federal eRulemaking Portal until March 25, 2025. Individuals may also request a hearing about the application by the same date.

The Drug Enforcement Administration (DEA) issued an Order to Show Cause to Laura M. Bellew, a nurse practitioner from New Mexico, proposing to revoke her DEA registration because she no longer has the authority to handle controlled substances in New Mexico. This is because her nursing licenses were suspended by the New Mexico State Board of Nursing in January 2023. Bellew did not request a hearing to contest the charges, effectively admitting the DEA's allegations. As a result, the DEA decided to revoke her registration and deny any pending applications related to controlled substances in New Mexico.

The Drug Enforcement Administration (DEA) has decided to revoke the registration of Jeffrey W. Young, Jr., a nurse practitioner from Tennessee, due to his lack of state authorization to handle controlled substances. Young's Tennessee nurse and advanced practice nurse licenses were both revoked, making him ineligible to dispense medications under state laws. Despite being given a chance, Young did not request a hearing to challenge this decision, leading the DEA to proceed with the revocation of his Certificate of Registration. This order will be effective from January 29, 2025.

SpecGx LLC has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances. The company intends to import specific drugs, including Tapentadol and Thebaine, for manufacturing purposes to create Active Pharmaceutical Ingredients. This notice allows registered manufacturers and other stakeholders to submit comments or request a hearing about this application by April 25, 2025. Approval for import will be strictly for manufacturing purposes and not for importing finished drug forms for sale.